Visual Abstract

Brugada syndrome (BrS) is a known cause of sudden cardiac death (SCD) characterized by abnormal electrocardiograms and fatal arrhythmias. The variants in KCND3 encoding the KV4.3 potassium-channel (the α-subunit of the Ito) have seldom been reported in BrS. This study aimed to identify novel KCND3 variants associated with BrS and elucidate BrS pathogenesis. High-depth targeted sequencing was performed and the electrophysiological properties of the variants were detected by whole-cell patch-clamp methods in a cultured-cell expressing system. The transcriptional levels of KV4.3 in different genotypes were studied by real-time PCR. Western blot was used to assess channel protein expression. A novel KCND3 heterozygous variant, c.1292G>A (Arg431His, R431H), was found in the proband. Whole-cell patch-clamp results revealed a gain-of-function phenotype in the variant, with peak Ito current density increased and faster recovery from inactivation. The expression of mutant Kv4.3 membrane protein increased and the cytoplasmic protein decreased, demonstrating that the membrane/cytoplasm ratio was significantly different. In conclusion, a novel KCND3 heterozygous variant was associated with BrS. The increased Ito current explained the critical role of KCND3 in the pathogenesis of BrS. Genetic screening for KCND3 could be useful for understanding the pathogenesis of BrS and providing effective risk stratification in the clinic.

1.
Brugada
J
,
Campuzano
O
,
Arbelo
E
,
Sarquella-Brugada
G
,
Brugada
R
.
Present Status of Brugada Syndrome: JACC State-of-the-Art Review
.
J Am Coll Cardiol
.
2018
Aug
;
72
(
9
):
1046
59
.
[PubMed]
0735-1097
2.
Haugaa
KH
,
Dan
GA
,
Iliodromitis
K
,
Lenarczyk
R
,
Marinskis
G
,
Osca
J
, et al
Management of patients with ventricular arrhythmias and prevention of sudden cardiac death-translating guidelines into practice: results of the European Heart Rhythm Association survey
.
Europace
.
2018
Sep
;
20
FI2
:
f249
53
.
[PubMed]
1099-5129
3.
Papadakis
M
,
Papatheodorou
E
,
Mellor
G
,
Raju
H
,
Bastiaenen
R
,
Wijeyeratne
Y
, et al
The Diagnostic Yield of Brugada Syndrome After Sudden Death With Normal Autopsy
.
J Am Coll Cardiol
.
2018
Mar
;
71
(
11
):
1204
14
.
[PubMed]
0735-1097
4.
Watanabe
H
,
Minamino
T
.
Genetics of Brugada syndrome
.
J Hum Genet
.
2016
Jan
;
61
(
1
):
57
60
.
[PubMed]
1434-5161
5.
Wong
LC
,
Behr
ER
.
Sudden unexplained death in infants and children: the role of undiagnosed inherited cardiac conditions
.
Europace
.
2014
Dec
;
16
(
12
):
1706
13
.
[PubMed]
1099-5129
6.
Hedley
PL
,
Jørgensen
P
,
Schlamowitz
S
,
Moolman-Smook
J
,
Kanters
JK
,
Corfield
VA
, et al
The genetic basis of Brugada syndrome: a mutation update
.
Hum Mutat
.
2009
Sep
;
30
(
9
):
1256
66
.
[PubMed]
1059-7794
7.
Priori
SG
,
Blomström-Lundqvist
C
.
2015 European Society of Cardiology Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death summarized by co-chairs
.
Eur Heart J
.
2015
Nov
;
36
(
41
):
2757
9
.
[PubMed]
0195-668X
8.
Antzelevitch
C
,
Brugada
P
,
Borggrefe
M
,
Brugada
J
,
Brugada
R
,
Corrado
D
, et al
Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association
.
Circulation
.
2005
Feb
;
111
(
5
):
659
70
.
[PubMed]
0009-7322
9.
Juang
JJ
,
Horie
M
.
Genetics of Brugada syndrome
.
J Arrhythm
.
2016
Oct
;
32
(
5
):
418
25
.
[PubMed]
1880-4276
10.
Kapplinger
JD
,
Tester
DJ
,
Alders
M
,
Benito
B
,
Berthet
M
,
Brugada
J
, et al
An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing
.
Heart Rhythm
.
2010
Jan
;
7
(
1
):
33
46
.
[PubMed]
1547-5271
11.
Gussak
I
,
Antzelevitch
C
,
Bjerregaard
P
,
Towbin
JA
,
Chaitman
BR
.
The Brugada syndrome: clinical, electrophysiologic and genetic aspects
.
J Am Coll Cardiol
.
1999
Jan
;
33
(
1
):
5
15
.
[PubMed]
0735-1097
12.
Antzelevitch
C
,
Yan
GX
.
J wave syndromes
.
Heart Rhythm
.
2010
Apr
;
7
(
4
):
549
58
.
[PubMed]
1547-5271
13.
Fish
JM
,
Antzelevitch
C
.
Cellular and ionic basis for the sex-related difference in the manifestation of the Brugada syndrome and progressive conduction disease phenotypes
.
J Electrocardiol
.
2003
;
36
Suppl
:
173
9
.
[PubMed]
0022-0736
14.
Antzelevitch
C
,
Yan
GX
,
Shimizu
W
.
Transmural dispersion of repolarization and arrhythmogenicity: the Brugada syndrome versus the long QT syndrome
.
J Electrocardiol
.
1999
;
32
Suppl
:
158
65
.
[PubMed]
0022-0736
15.
Kääb
S
,
Dixon
J
,
Duc
J
,
Ashen
D
,
Näbauer
M
,
Beuckelmann
DJ
, et al
Molecular basis of transient outward potassium current downregulation in human heart failure: a decrease in Kv4.3 mRNA correlates with a reduction in current density
.
Circulation
.
1998
Oct
;
98
(
14
):
1383
93
.
[PubMed]
0009-7322
16.
Patel
SP
,
Campbell
DL
.
Transient outward potassium current, ‘Ito’, phenotypes in the mammalian left ventricle: underlying molecular, cellular and biophysical mechanisms
.
J Physiol
.
2005
Nov
;
569
(
Pt 1
):
7
39
.
[PubMed]
0022-3751
17.
Niwa
N
,
Nerbonne
JM
.
Molecular determinants of cardiac transient outward potassium current (I(to)) expression and regulation
.
J Mol Cell Cardiol
.
2010
Jan
;
48
(
1
):
12
25
.
[PubMed]
0022-2828
18.
Takayama
K
,
Ohno
S
,
Ding
WG
,
Ashihara
T
,
Fukumoto
D
,
Wada
Y
,
Makiyama
T
,
Kise
H
,
Hoshiai
M
,
Matsuura
H
,
Horie
M
:
A de novo gain-of-function KCND3 mutation in early repolarization syndrome.
Heart Rhythm
2019
:;Epub June 4.
19.
Giudicessi
JR
,
Ye
D
,
Tester
DJ
,
Crotti
L
,
Mugione
A
,
Nesterenko
VV
, et al
Transient outward current (I(to)) gain-of-function mutations in the KCND3-encoded Kv4.3 potassium channel and Brugada syndrome
.
Heart Rhythm
.
2011
Jul
;
8
(
7
):
1024
32
.
[PubMed]
1547-5271
20.
Giudicessi
JR
,
Ye
D
,
Kritzberger
CJ
,
Nesterenko
VV
,
Tester
DJ
,
Antzelevitch
C
, et al
Novel mutations in the KCND3-encoded Kv4.3 K+ channel associated with autopsy-negative sudden unexplained death
.
Hum Mutat
.
2012
Jun
;
33
(
6
):
989
97
.
[PubMed]
1059-7794
21.
Calloe
K
,
Cordeiro
JM
,
Di Diego
JM
,
Hansen
RS
,
Grunnet
M
,
Olesen
SP
, et al
A transient outward potassium current activator recapitulates the electrocardiographic manifestations of Brugada syndrome
.
Cardiovasc Res
.
2009
Mar
;
81
(
4
):
686
94
.
[PubMed]
0008-6363
22.
Greenstein
JL
,
Wu
R
,
Po
S
,
Tomaselli
GF
,
Winslow
RL
.
Role of the calcium-independent transient outward current I(to1) in shaping action potential morphology and duration
.
Circ Res
.
2000
Nov
;
87
(
11
):
1026
33
.
[PubMed]
0009-7330
23.
Olesen
MS
,
Refsgaard
L
,
Holst
AG
,
Larsen
AP
,
Grubb
S
,
Haunsø
S
, et al
A novel KCND3 gain-of-function mutation associated with early-onset of persistent lone atrial fibrillation
.
Cardiovasc Res
.
2013
Jun
;
98
(
3
):
488
95
.
[PubMed]
0008-6363
24.
Olesen
MS
,
Andreasen
L
,
Jabbari
J
,
Refsgaard
L
,
Haunsø
S
,
Olesen
SP
, et al
Very early-onset lone atrial fibrillation patients have a high prevalence of rare variants in genes previously associated with atrial fibrillation
.
Heart Rhythm
.
2014
Feb
;
11
(
2
):
246
51
.
[PubMed]
1547-5271
25.
Wang
H
,
Yan
Y
,
Liu
Q
,
Huang
Y
,
Shen
Y
,
Chen
L
, et al
Structural basis for modulation of Kv4 K+ channels by auxiliary KChIP subunits
.
Nat Neurosci
.
2007
Jan
;
10
(
1
):
32
9
.
[PubMed]
1097-6256
26.
Callsen
B
,
Isbrandt
D
,
Sauter
K
,
Hartmann
LS
,
Pongs
O
,
Bähring
R
.
Contribution of N- and C-terminal Kv4.2 channel domains to KChIP interaction [corrected]
.
[corrected]
.
J Physiol
.
2005
Oct
;
568
(
Pt 2
):
397
412
.
[PubMed]
0022-3751
27.
Deschênes
I
,
Tomaselli
GF
.
Modulation of Kv4.3 current by accessory subunits
.
FEBS Lett
.
2002
Sep
;
528
(
1-3
):
183
8
.
[PubMed]
0014-5793
28.
Ohya
S
,
Tanaka
M
,
Oku
T
,
Furuyama
T
,
Mori
N
,
Giles
WR
, et al
Regional expression of the splice variants of Kv4.3 in rat brain and effects of C-terminus deletion on expressed K+ currents
.
Life Sci
.
2001
Mar
;
68
(
15
):
1703
16
.
[PubMed]
0024-3205
29.
Abbott
GW
.
β Subunits Control the Effects of Human Kv4.3 Potassium Channel Phosphorylation
.
Front Physiol
.
2017
Sep
;
8
:
646
.
[PubMed]
1664-042X
30.
Nakamura
TY
,
Coetzee
WA
,
Vega-Saenz De Miera
E
,
Artman
M
,
Rudy
B
.
Modulation of Kv4 channels, key components of rat ventricular transient outward K+ current, by PKC
.
Am J Physiol
.
1997
Oct
;
273
(
4
):
H1775
86
.
[PubMed]
0002-9513
31.
Groen
C
,
Bähring
R
.
Modulation of human Kv4.3/KChIP2 channel inactivation kinetics by cytoplasmic Ca2
.
Pflugers Arch
.
2017
Nov
;
469
(
11
):
1457
70
.
[PubMed]
0031-6768
32.
Sergeant
GP
,
Ohya
S
,
Reihill
JA
,
Perrino
BA
,
Amberg
GC
,
Imaizumi
Y
, et al
Regulation of Kv4.3 currents by Ca2+/calmodulin-dependent protein kinase II
.
Am J Physiol Cell Physiol
.
2005
Feb
;
288
(
2
):
C304
13
.
[PubMed]
0363-6143
33.
Hatano
N
,
Ohya
S
,
Muraki
K
,
Clark
RB
,
Giles
WR
,
Imaizumi
Y
.
Two arginines in the cytoplasmic C-terminal domain are essential for voltage-dependent regulation of A-type K+ current in the Kv4 channel subfamily
.
J Biol Chem
.
2004
Feb
;
279
(
7
):
5450
9
.
[PubMed]
0021-9258
34.
Richards
S
,
Aziz
N
,
Bale
S
,
Bick
D
,
Das
S
,
Gastier-Foster
J
, et al;
ACMG Laboratory Quality Assurance Committee
.
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
.
Genet Med
.
2015
May
;
17
(
5
):
405
24
.
[PubMed]
1098-3600
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.